David A. Dodd Acquires 10,000 Shares of GeoVax Labs, Inc. (NASDAQ:GOVX) Stock

GeoVax Labs, Inc. (NASDAQ:GOVX) CEO David A. Dodd acquired 10,000 shares of the company’s stock in a transaction on Tuesday, April 1st. The stock was acquired at an average cost of $1.08 per share, with a total value of $10,800.00. Following the completion of the purchase, the chief executive officer now directly owns 36,661 shares in the company, valued at approximately $39,593.88. This represents a 37.51 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link.

GeoVax Labs Stock Up 1.9 %

Shares of NASDAQ GOVX traded up $0.02 during trading on Tuesday, hitting $1.08. The company had a trading volume of 329,440 shares, compared to its average volume of 617,522. The firm has a market capitalization of $10.19 million, a price-to-earnings ratio of -0.19 and a beta of 3.06. The stock has a fifty day simple moving average of $1.64 and a two-hundred day simple moving average of $2.11. GeoVax Labs, Inc. has a fifty-two week low of $1.03 and a fifty-two week high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last posted its earnings results on Thursday, March 27th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.79) by $0.49. The firm had revenue of $3.00 million during the quarter, compared to analyst estimates of $2.38 million. On average, analysts anticipate that GeoVax Labs, Inc. will post -4.49 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, D. Boral Capital reiterated a “buy” rating and issued a $18.00 target price on shares of GeoVax Labs in a research note on Friday. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $14.20.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in GOVX. Northern Trust Corp purchased a new stake in shares of GeoVax Labs in the fourth quarter valued at about $29,000. Geode Capital Management LLC grew its position in shares of GeoVax Labs by 59.0% in the fourth quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after purchasing an additional 33,440 shares during the period. Virtu Financial LLC purchased a new position in shares of GeoVax Labs in the 3rd quarter worth about $97,000. Finally, Citadel Advisors LLC purchased a new position in GeoVax Labs in the fourth quarter valued at about $104,000. Hedge funds and other institutional investors own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.